Clinical trial NCT01669746: A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)
Official title: A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Androgenetic Alopecia
Male Pattern Baldness
Female Pattern Baldness
Keywords: Androgenetic Alopecia
Male Pattern Baldness
Female Pattern Baldness
Hair Loss
Baldness
Lead sponsor: Aderans Research Institute
Sponsor class: INDUSTRY
First posted: 2012-08-21
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.


Eligibility criteria: Inclusion Criteria:

* Male and female volunteers 18-50 years old, inclusive.
* Women of childbearing potential must use an adequate form of contraception during study participation.
* Hair loss consistent with Grade III-Vertex, IV, or V based on the based on the Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle, or class 1 or class 2 based on the Ludwig scale.
* Able to provide informed consent after risks and benefits of the study have been explained.
* Be willing to undergo all study procedures.
* Ability to communicate effectively with study personnel.
* Have no clinically significant disease or abnormal laboratory evaluations taken at the screening visit.
* Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study; also agrees to abstain from shaving the head during the course of the study.

Exclusion Criteria:

* Women who are pregnant or lactating.
* Known sensitivity to DMEM/F-12 or any component of the study material.
* Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
* Subjects who have used minoxidil or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
* A history of drug or alcohol abuse within 1 year of study enrollment.
* Participation in any other investigational study within 30 days or six half lives of its biologic activity, whichever is longer, before the scalp excision visit(s), and during the time enrolled in this study.
* Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
* Clinically significant symptoms of any acute illness within 30 days prior to excision day.
* Any condition that compromises the ability to understand or comply with study requirements.
* Clinically significant abnormal laboratory parameters.
* A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
* Clinically significant dermatologic condition in donation or study zones.
* Prior surgery in the donor or study zones.
* Insufficient hair or scarring in the donor area that might impact cell growth.
* Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.

Primary outcomes:
measure: Change from baseline in hair number
timeFrame: 24 weeks post-injection
measure: Change from baseline in hair width
timeFrame: 24 weeks post-injection
measure: Time course of any treatment benefit
timeFrame: 24 week post-injection
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Radiant Research, Inc.
state: Arizona
city: Santa Rosa
country: United States
facility: Radiant Research, Inc.
state: California
city: Denver
country: United States
facility: Radiant Research, Inc.
state: Colorado
city: Pinellas Park
country: United States
facility: Radiant Research, Inc.
state: Florida
city: Akron
country: United States
facility: Radiant Research, Inc.
state: Ohio
city: Greer
country: United States
facility: Radiant Research, Inc.
state: South Carolina
city: San Antonio
country: United States
facility: Radiant Research, Inc.
state: Texas
Study officials:
References: